183 related articles for article (PubMed ID: 27258230)
1. Sex-Related Differences in Inflammatory and Immune Activation Markers Before and After Combined Antiretroviral Therapy Initiation.
Mathad JS; Gupte N; Balagopal A; Asmuth D; Hakim J; Santos B; Riviere C; Hosseinipour M; Sugandhavesa P; Infante R; Pillay S; Cardoso SW; Mwelase N; Pawar J; Berendes S; Kumarasamy N; Andrade BB; Campbell TB; Currier JS; Cohn SE; Gupta A;
J Acquir Immune Defic Syndr; 2016 Oct; 73(2):123-9. PubMed ID: 27258230
[TBL] [Abstract][Full Text] [Related]
2. Pre-cART Elevation of CRP and CD4+ T-Cell Immune Activation Associated With HIV Clinical Progression in a Multinational Case-Cohort Study.
Balagopal A; Asmuth DM; Yang WT; Campbell TB; Gupte N; Smeaton L; Kanyama C; Grinsztejn B; Santos B; Supparatpinyo K; Badal-Faesen S; Lama JR; Lalloo UG; Zulu F; Pawar JS; Riviere C; Kumarasamy N; Hakim J; Li XD; Pollard RB; Semba RD; Thomas DL; Bollinger RC; Gupta A;
J Acquir Immune Defic Syndr; 2015 Oct; 70(2):163-71. PubMed ID: 26017661
[TBL] [Abstract][Full Text] [Related]
3. Soluble biomarkers of immune activation and inflammation in HIV infection: impact of 2 years of effective first-line combination antiretroviral therapy.
Hattab S; Guiguet M; Carcelain G; Fourati S; Guihot A; Autran B; Caby F; Marcelin AG; Costagliola D; Katlama C
HIV Med; 2015 Oct; 16(9):553-62. PubMed ID: 25944318
[TBL] [Abstract][Full Text] [Related]
4. Suboptimal Adherence to Combination Antiretroviral Therapy Is Associated With Higher Levels of Inflammation Despite HIV Suppression.
Castillo-Mancilla JR; Brown TT; Erlandson KM; Palella FJ; Gardner EM; Macatangay BJ; Breen EC; Jacobson LP; Anderson PL; Wada NI
Clin Infect Dis; 2016 Dec; 63(12):1661-1667. PubMed ID: 27660234
[TBL] [Abstract][Full Text] [Related]
5. Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients.
Bastard JP; Soulié C; Fellahi S; Haïm-Boukobza S; Simon A; Katlama C; Calvez V; Marcelin AG; Capeau J
Antivir Ther; 2012; 17(5):915-9. PubMed ID: 22436412
[TBL] [Abstract][Full Text] [Related]
6. Brief Report: No Evidence for an Association Between Statin Use and Lower Biomarkers of HIV Persistence or Immune Activation/Inflammation During Effective ART.
Bedimo RJ; Mar H; Bosch RJ; Drechsler H; Cyktor JC; Macatangay BJC; Lalama C; Rinaldo C; Collier A; Godfrey C; Hogg E; Hensel C; Eron JJ; Mcmahon DK; Mellors JW; Tebas P; Gandhi RT;
J Acquir Immune Defic Syndr; 2019 Oct; 82(2):e27-e31. PubMed ID: 31335587
[TBL] [Abstract][Full Text] [Related]
7. C-reactive protein (CRP), interferon gamma-inducible protein 10 (IP-10), and lipopolysaccharide (LPS) are associated with risk of tuberculosis after initiation of antiretroviral therapy in resource-limited settings.
Tenforde MW; Gupte N; Dowdy DW; Asmuth DM; Balagopal A; Pollard RB; Sugandhavesa P; Lama JR; Pillay S; Cardoso SW; Pawar J; Santos B; Riviere C; Mwelase N; Kanyama C; Kumwenda J; Hakim JG; Kumarasamy N; Bollinger R; Semba RD; Campbell TB; Gupta A;
PLoS One; 2015; 10(2):e0117424. PubMed ID: 25719208
[TBL] [Abstract][Full Text] [Related]
8. A 12 week longitudinal study of microbial translocation and systemic inflammation in undernourished HIV-infected Zambians initiating antiretroviral therapy.
Canipe A; Chidumayo T; Blevins M; Bestawros M; Bala J; Kelly P; Filteau S; Shepherd BE; Heimburger DC; Koethe JR
BMC Infect Dis; 2014 Sep; 14():521. PubMed ID: 25266928
[TBL] [Abstract][Full Text] [Related]
9. Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection.
Sereti I; Krebs SJ; Phanuphak N; Fletcher JL; Slike B; Pinyakorn S; O'Connell RJ; Rupert A; Chomont N; Valcour V; Kim JH; Robb ML; Michael NL; Douek DC; Ananworanich J; Utay NS;
Clin Infect Dis; 2017 Jan; 64(2):124-131. PubMed ID: 27737952
[TBL] [Abstract][Full Text] [Related]
10. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men.
Sterling TR; Vlahov D; Astemborski J; Hoover DR; Margolick JB; Quinn TC
N Engl J Med; 2001 Mar; 344(10):720-5. PubMed ID: 11236775
[TBL] [Abstract][Full Text] [Related]
11. Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy.
Belmonti S; Lombardi F; Quiros-Roldan E; Latini A; Castagna A; Borghetti A; Baldin G; Ciccullo A; Cauda R; De Luca A; Di Giambenedetto S;
J Antimicrob Chemother; 2018 Jul; 73(7):1949-1954. PubMed ID: 29788156
[TBL] [Abstract][Full Text] [Related]
12. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1.
Emu B; Fessel J; Schrader S; Kumar P; Richmond G; Win S; Weinheimer S; Marsolais C; Lewis S
N Engl J Med; 2018 Aug; 379(7):645-654. PubMed ID: 30110589
[TBL] [Abstract][Full Text] [Related]
13. Switching to dual antiretroviral regimens is associated with improvement or no changes in activation and inflammation markers in virologically suppressed HIV-1-infected patients: the TRILOBITHE pilot study.
Vallejo A; Molano M; Monsalvo-Hernando M; Hernández-Walias F; Fontecha-Ortega M; Casado JL
HIV Med; 2019 Sep; 20(8):555-560. PubMed ID: 31131528
[TBL] [Abstract][Full Text] [Related]
14. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial.
Calmy A; Gayet-Ageron A; Montecucco F; Nguyen A; Mach F; Burger F; Ubolyam S; Carr A; Ruxungtham K; Hirschel B; Ananworanich J;
AIDS; 2009 May; 23(8):929-39. PubMed ID: 19425222
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M;
N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645
[TBL] [Abstract][Full Text] [Related]
16. Long-term Therapeutic Impact of the Timing of Antiretroviral Therapy in Patients Diagnosed With Primary Human Immunodeficiency Virus Type 1 Infection.
Novelli S; Lécuroux C; Avettand-Fenoel V; Seng R; Essat A; Morlat P; Viard JP; Rouzioux C; Meyer L; Goujard C
Clin Infect Dis; 2018 May; 66(10):1519-1527. PubMed ID: 29211834
[TBL] [Abstract][Full Text] [Related]
17. Shorter telomere length predicts poorer immunological recovery in virologically suppressed HIV-1-infected patients treated with combined antiretroviral therapy.
Blanco JR; Jarrin I; Martinez A; Siles E; Larrayoz IM; Cañuelo A; Gutierrez F; Gonzalez-Garcia J; Vidal F; Moreno S;
J Acquir Immune Defic Syndr; 2015 Jan; 68(1):21-9. PubMed ID: 25321176
[TBL] [Abstract][Full Text] [Related]
18. Meeting the WHO 90% target: antiretroviral treatment efficacy in Poland is associated with baseline clinical patient characteristics.
Parczewski M; Siwak E; Leszczyszyn-Pynka M; Cielniak I; Burkacka E; Pulik P; Witor A; Muller K; Zasik E; Grzeszczuk A; Jankowska M; Lemańska M; Olczak A; Grąbczewska E; Szymczak A; Gąsiorowski J; Szetela B; Bociąga-Jasik M; Skwara P; Witak-Jędra M; Jabłonowska E; Wójcik-Cichy K; Kamerys J; Janczarek M; Krankowska D; Mikuła T; Kozieł K; Bielec D; Stempkowska J; Kocbach A; Błudzin W; Horban A
J Int AIDS Soc; 2017 Jul; 20(1):21847. PubMed ID: 28715160
[TBL] [Abstract][Full Text] [Related]
19. Combined effect of sex and age in response to antiretroviral therapy in HIV-infected patients.
Blanco JR; Jarrin I; Pérez-Elías MJ; Gutiérrez F; Hernández-Quero J; Portilla J; Dalmau D; Moreno S; Hernando V;
Antivir Ther; 2017; 22(1):21-29. PubMed ID: 27467968
[TBL] [Abstract][Full Text] [Related]
20. Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial.
Katlama C; Clotet B; Plettenberg A; Jost J; Arasteh K; Bernasconi E; Jeantils V; Cutrell A; Stone C; Purdon S;
HIV Med; 2001 Jan; 2(1):27-34. PubMed ID: 11737373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
